Wikkon
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese market leader in urological shockwave lithotripsy and therapy devices, with FDA-cleared systems and global distribution.
UrologyMusculoskeletal
Technology Platform
Extracorporeal shockwave generation and targeting systems for lithotripsy (stone fragmentation) and tissue regeneration therapies, incorporating precision engineering, imaging integration, and proprietary focusing technology.
Opportunities
Expansion into U.S.
and Western markets following FDA clearance of U200 system, and broadening ESWT applications into adjacent musculoskeletal and rehabilitation therapy markets globally.
Risk Factors
Intense competition from established Western medtech companies and emerging Chinese manufacturers, regulatory hurdles in new markets, and potential technology commoditization in shockwave therapy segments.
Competitive Landscape
Competes with Dornier MedTech, Siemens Healthineers, Storz Medical, and Chinese manufacturers like Haifu Medical; differentiates through cost-effective yet technologically advanced systems with Dornier partnership validation and extensive installed base in emerging markets.